Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.

Heller, James H; Spiridigliozzi, Gail A; Crissman, Blythe G; Sullivan, Jennifer A; Eells, Rebecca L; Li, Jennifer S; Doraiswamy, P Murali; Krishnan, K Ranga; Kishnani, Priya S

Heller, James H; Spiridigliozzi, Gail A; Crissman, Blythe G; Sullivan, Jennifer A; Eells, Rebecca L; Li, Jennifer S; Doraiswamy, P Murali; Krishnan, K Ranga; Kishnani, Priya S.

Affiliation

Heller JH; Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

J Child Adolesc Psychopharmacol ; 16(6): 755-65, 2006 Dec.

Article in En | MEDLINE | ID: mdl-17201619

Subject(s)

Cholinesterase Inhibitors/therapeutic use; Down Syndrome/drug therapy; Phenylcarbamates/therapeutic use; Adaptation, Psychological/drug effects; Adolescent; Attention/drug effects; Child; Cholinesterase Inhibitors/administration & dosage; Cholinesterase Inhibitors/adverse effects; Down Syndrome/psychology; Female; Humans; Language; Male; Memory/drug effects; Patient Compliance; Phenylcarbamates/administration & dosage; Phenylcarbamates/adverse effects; Rivastigmine; Verbal Behavior/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cholinesterase Inhibitors / Down Syndrome / Phenylcarbamates Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: J Child Adolesc Psychopharmacol Journal subject: PEDIATRIA / PSICOFARMACOLOGIA Year: 2006 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google